Oncology Medical News about advanced non-small-cell lunf cancer;Sorafenib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non–small-cell lung cancer
Journal of Clinical Oncology, 09/10/09

Blumenschein GR et al. – Continuous treatment with sorafenib 400 mg twice daily was associated with disease stabilization in patients with advanced NSCLC.

Methods

Phase II, single-arm, multicenter study
Patients with relapsed or refractory advanced NSCLC received sorafenib 400 mg orally twice daily until tumor progression or an unacceptable drug-related toxicity occurred

Results

Of 54 patients enrolled, 52 received sorafenib
The predominant histologies were adenocarcinoma (54%) and squamous cell carcinoma (31%)
No complete or partial responses were observed
SD was achieved in 30 (59%) of the 51 patients who were evaluable for efficacy
4patients with SD developed tumor cavitation
Median progression-free survival (PFS) was 2.7 months, and median overall survival was 6.7 months
Patients with SD had a median PFS of 5.5 months
Major grades 3-4, treatment-related toxicities included hand-foot skin reaction (10%), hypertension (4%), fatigue (2%), and diarrhea (2%)
9patients died within a 30-day period after discontinuing sorafenib, and one patient experienced pulmonary hemorrhage that was considered drug related

<< Previous
Breast cancer risk in female survivors of Hodgkin's lymphoma:...

Next >>
5-year survival in patients with relapsed or refractory chronic...